Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells (original) (raw)
T. Yamamoto, S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, and K. Toyoshima. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature319:230–240 (1986). ArticlePubMedCAS Google Scholar
C. I. Bargmann, M. C. Hung, and R. A. Weinberg. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature319:226–230 (1986). ArticlePubMedCAS Google Scholar
M. Tan, J. Yao, and D. Yu. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasispotential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1199–1205 (1997). PubMedCAS Google Scholar
D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235:177–182 (1987). ArticlePubMedCAS Google Scholar
M. Toi, K. Horiguchi, H. Bando, S. Saji, and L. W. C. Chow. Trastuzumab: updates and future issues. Cancer Chemother.Pharmacol. 56:s94–s99 (2005). ArticleCAS Google Scholar
P. Carter, L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, and W. L. Wong. Humanization of an anti-p185her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA89:4285–4289 (1992). ArticlePubMedCAS Google Scholar
J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, and L. Norton. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER/_neu_-overexpressing metastatic breast cancer. J. Clin. Oncol.14:737–744 (1996). PubMedCAS Google Scholar
M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in woman who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol.17:2639–2648 (1999). PubMedCAS Google Scholar
D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cnacer that overexpresses HER2. N. Engl. J. Med. 344:783–792 (2001). ArticlePubMedCAS Google Scholar
E. K. Rowinsky, and R. C. Donehower. Paclitaxel (Taxol). N. Engl. J. Med.332:1004–1014 (1995). ArticlePubMedCAS Google Scholar
T. M. Mekhail, and M. Markman. Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 3:755–766 (2002). ArticlePubMedCAS Google Scholar
A. M. Yvon, P. Wadsworth, and M. A. Jordan. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Bio. Cell10:947–959 (1999). CAS Google Scholar
A. Goncalves, D. Braguer, K. Kamath, L. Martello, C. Briand, S. Horwitz, L. Wilson, and M. A. Jordan. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc. Natl. Acad. Sci. USA98:11737–11742 (2001). ArticlePubMedCAS Google Scholar
M. A. Jordan, and L. Wilson. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4:253–265 (2004). ArticlePubMedCAS Google Scholar
M. D. Pegram, A. Lopez, G. Konecny, and D. J. Slamon. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin. Oncol.27(6 Suppl 11):21–25 (2000). PubMedCAS Google Scholar
V. Dieras, P. Beuzeboc, V. Laurence, J. Y. Pierga, and P. Pouillart. Interaction between Herceptin and taxanes. Oncology61(Suppl 2):43–49 (2001). PubMed Google Scholar
S. Suzuki, S. Watanabe, T. Masuko, and Y. Hashimoto. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with polyethylene glycol. Biochem. Biophys. Acta1245:22–29 (1995). Google Scholar
S. M. Nam, H. S. Kim, W. S. Ahn, and Y. S. Park. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells. Oncol. Res. 11:9–16 (1999). PubMedCAS Google Scholar
G. Pagnan, P. G. Montaldo, F. Pastorino, L. Raffaghello, M. Kirchmeier, and T. M. Allen. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer81:268–274 (1999). ArticlePubMedCAS Google Scholar
K. R. Reddy. Controlled-release, pegylation, liposomal formulation: new mechanisms in the delivery of injectable drugs. Drug Deliv. 34:915–923 (2000). CAS Google Scholar
J. W. Park, K. Hong, D. B. Kirpotin, D. Papahadjopoulos, and C. C. Benz. Immunoliposomes for cancer treatment. Adv. Pharmacol. 40:399–435 (1997). ArticlePubMedCAS Google Scholar
J. S. Chen, K. L. Lan, and M. C. Hung. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist. Updat. 6:129–136 (2003). ArticlePubMedCAS Google Scholar
J. W. Park, K. Hong, P. Carter, H. Asgari, L. Y. Guo, G. A. Keller, C. Wirth, R. Shalaby, C. Kotts, W. I. Wood, D. Papahadjopoulos, and C. C. Benz. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA92:1327–1331 (1995). ArticlePubMedCAS Google Scholar
T. Yang, M. K. Choi, F. D. Cui, J. S. Kim, S. J. Chung, C. K. Shim, and D. D. Kim. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Control. Release120:169–177 (2007). ArticlePubMedCAS Google Scholar
T. Yang, F. D. Cui, M. K. Choi, J. W. Cho, S. J. Chung, C. K. Shim, and D. D. Kim. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int. J. Pharm.338:317–326 (2007). ArticlePubMedCAS Google Scholar
U. B. Nielsen, D. B. Kirpotin, E. M. Pickering, K. Hong, J. W. Park, M. R. Shalaby, Y. Shao, C. C. Benz, and J. D. Marks. Therapeutic efficacy of anti-ErbB2 immnoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta1591:109–118 (2002). ArticlePubMedCAS Google Scholar
C. Fonseca, J. N. Moreira, C. J. Ciudad, M. C. Pedroso de Lima, and S. Simões. Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur. J. Pharm. Biopharm.59:359–366 (2005). ArticlePubMedCAS Google Scholar
K. Laginha, D. Mumbengegwi, and T. Allen. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim. Biophys. Acta1711:25–32 (2005). ArticlePubMedCAS Google Scholar
P. R. Twentyman, and M. Luscombe. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer56:279–285 (1987). PubMedCAS Google Scholar
A. Sharma, U. S. Sharma, and R. M. Straubinger. Paclitaxel-liposomes for intracavity therapy of intraperitoneal P388 leukemia. Cancer Lett. 107:265–272 (1996). ArticlePubMedCAS Google Scholar
C. X. Wang, D. C. Koay, A. Edwards, Z. Lu, G. Mor, I. T. Ocal, and M. P. DiGiovanna. In vitro and in vivo effects of combination of trastuzumab (Herceptin) and tamoxifen in breast cancer. Breast Cancer Res. Treat. 92:251–263 (2005). ArticlePubMedCAS Google Scholar
N. Maeda, Y. Takeuchi, M. Takada, Y. Sadzuka, Y. Namba, and N. Oku. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release100:41–52 (2004). ArticlePubMedCAS Google Scholar
M. Owais, and C. M. Gupta. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur. J. Biochem. 267:3946–3956 (2000). ArticlePubMedCAS Google Scholar
S. C. Semple, A. Chonn, and P. R. Cullis. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry35:2521–2525 (1996). ArticlePubMedCAS Google Scholar
M. C. Woodle. Controlling liposomal blood clearance by surface-grafted polymers. Adv. Drug Deliv. Rev. 32:139–152 (1998). ArticlePubMedCAS Google Scholar
Y. P. Hu, N. Henry-Toulme, and J. Robert. Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastroma cells. Eur. J. Cancer31:389–394 (1995). Article Google Scholar
M. L. Immordino, P. Brusa, S. Arpicco, B. Stella, F. Dosio, and L. Cattel. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing decetaxel. J. Control. Release91:417–429 (2003). ArticlePubMedCAS Google Scholar
P. Crosasso, M. Ceruti, P. Brusa, S. Arpicco, and L. Cattel. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control. Release63:19–30 (2000). ArticlePubMedCAS Google Scholar
P. Carter. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. CancerNov1:118–129 (2001). ArticleCAS Google Scholar
R. J. Pietras, B. M. Fendly, V. R. Chazin, M. D. Pegram, S. B. Howell, and D. J. Slamon. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene9:1829–1838 (1994). PubMedCAS Google Scholar
J. Baselga, L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825–2831 (1998). PubMedCAS Google Scholar
A. Ito, Y. Kuga, H. Honda, H. Kikkawa, A. Horiuchi, Y. Watanabe, and T. Kobayashi. Magnetic nanoparticle-loaded anti-immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett. 212:167–175 (2004). ArticlePubMedCAS Google Scholar
F. Valeriote, and H. Lin. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother. Rep. 59:895–900 (1975). PubMedCAS Google Scholar
U. Massing, and S. Fuxius. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist. Updat. 3:171–177 (2003). Article Google Scholar
E. Mastrobattista, G. A. Koning, and G. Storm. Immunoliposomes for the targeted delivery of anticancer drugs. Adv. Drug Deliv. Rev.40:103–127 (1999). ArticlePubMedCAS Google Scholar